Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis

European Heart Journal

Volumn 19, Issue 10, 1998, Pages 1538-1546

  Makkar, Raj R ^a,c   Eigler, N L ^a   Kaul, S ^a   Frimerman, A ^a   Nakamura, M ^a   Shah, P K ^a   Forrester, J S ^a   Herbert, J M ^b   Litvack, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANOFI   (France)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Platelets; Stent; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PERFUSION; PRIORITY JOURNAL; SHEAR RATE; STATISTICAL ANALYSIS; STENT; SWINE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBUS;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; ASPIRIN; BLEEDING TIME; BLOOD PLATELETS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT OCCLUSION, VASCULAR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STENTS; SWINE; TICLOPIDINE;

EID: 0032189692     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1042     Document Type: Article

References (39)

1. [1] Lemaitre DT, Barber AP, Mullen MG. Interventional cardiology. The Cowen Report, 1995; 6: 1-32.
2. [2] Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
3. [3] Serruys PW, DeJaegere P, Kiemeneij F et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
4. [4] Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stent. N Engl J Med 1996; 334: 1084-9.
5. [5] Serruys PW, Emanuelsson HV, Van der Giessen WJ et al. on behalf of the Benestent-II study group. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 1996; 93: 412-22.
6. [6] Nath FC, Muller DW, Ellis SG et al. Thrombosis of a flexible coil coronary extent: frequency, predictors and clinical outcome. J Am Coll Cardiol 1993; 21: 622-7.
7. [7] Liu MW, Voorhees III WD, Agrawal S, Dean LS, Roubin GS. Stratification of the risk of thrombosis after intracoronary stenting for threatened or acute closure complicating coronary balloon angioplasty: a Cook registry study. Am Heart J 1995; 130: 8-13.
8. [8] Haude M, Erbel R, Issa H et al. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am Heart J 1993; 126: 15-22.
9. [9] Roubin GS, Cannon AD, Agrawal SK et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: 916-27.
10. [10] Hearn JA, King III SB, Douglas Jr JS, Carlin SF, Lembo NJ, Ghazzal ZMB. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty: initial results with a balloon expandable stainless steel design. Circulation 1993; 88: 2086-96.
11. [11] Hasdai D, Garratt KN, Holmes Jr DR, Berger PB, Schwartz RS, Bell MR. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996; 28: 361-7.
12. [12] Makkar RR, Kaul S, Nakamura M et al. Modulation of acute stent thrombosis by metal surface characteristics and shear rate (Abstr). Circulation 1995; 92: 0140.
13. [13] Schror K. Antiplatelet drugs. A comparative view. Drugs 1995; 50: 7-28.
14. [14] Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28: 1236-8.
15. [15] Roald HE, Barstad RM, Kierulf P, Skjorten F, Dickinson JP, Kieffer G, Sakariassen KS. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994; 71: 655-62.
16. [16] Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of Indium 111-labelled platelets on collagen, subendothelium, and expanded polyytetra-fluoroethylene. J Lab Clin Med 1987; 110: 706-18.
17. [17] Born GVR, Gross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-95.
18. [18] Rath B, Bennett DH. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal angioplasty. Br Heart J 1990; 63: 18-21.
19. [19] Mills DC, Puri R, Hu CJ et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430-6.
20. [20] Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2-methylthio ADP to rat platelets - effect of clopidogrel and ticlopidine. Pharm Exp Ther 1994; 269: 772-7.
21. [21] Samama CM, Bonnin P, Bonneau M et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992; 68: 500-5.
22. -1 A. Thromb Haemost 1994; 72: 313-7.
23. [23] Yao SK, Ober JC, Ferguson JJ et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267(2 Pt 2): H488-93.
24. [24] Herbert JM, Bernat A, Sainte-Marie M, Do F, Rinaldi M. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, a streptokinase-induced thrombolysis in the rabbit. Thromb Haemost 1993; 69: 268-71.
25. [25] Herbert JM, Sissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993; 13: 1171-9.
26. [26] Herbert JM, Bernat A, Maffrand JP. Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. Thromb Res 1993; 71: 433-41.
27. [27] Makkar RR, Litvack F, Kaul S, Forrester J, Eigler N. Microscopic mechanisms of stent thrombosis; role of 7E3 antibody (Abstr). Circulation 1996; 94: 1-260.
28. [28] Kaul S, Makkar RR, Eigler NL et al. Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO: an ex vivo porcine arteriovenous shunt study. Circulation 1996; 94: 2228-34.
29. [29] Makkar RR, Litvack F, Eigler NL et al. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation 1997; 95: 1015-21.
30. [30] Van Beusekom HMM, Van Der Giessen WJ, Van Suylen RJ, Bos E, Bosnian FT, Serruys PW. Histology after stenting of human saphenous vein grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993; 21: 45-53.
31. [31] Kroll MH, Hellums JD, Guo Z et al. Protein kinase C is activated in platelets subjected to pathological shear stress. J Biol Chem 1993; 268: 3520-4.
32. [32] Yao SK, Ober JC, McNatt J et al. ADP plays an important role in mediating platelets aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: 39-48.
33. [33] Humbert M, Nurden P, Bihour C et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996; 16: 1532-43.
34. [34] Makkar R, Litvack F, Kaul S, Zeng H, Eigler N. High-shear overrides the antithrombotic effects of aspirin on stent thrombosis (Abstr). J Am Coll Cardiol 1997; 27: 354A.
35. [35] Maalej N, Folts D. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 1996; 93: 1201-5.
36. [36] Yao SK, McNatt J, Cui K et al. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Circulation 1993; 88: 2888-93.
37. [37] The EPIC investigators. Use of Monoclonal antibody directed against the plateletglycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1995; 330: 956-61.
38. [38] CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1997; 348: 1329-39.
39. [39] Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and hemostasis: basic principles and applications. Thromb Haemost 1986; 55: 415-35.